Lipid lowering treatment of severe hypertriglyceridemia with acute pancreatitis caused by everolimus in a patient with a neuroendocrine tumor
| Autor: | R Vera García, A Irigaray Echarri, E Muruzábal Huarte, J De Carlos Artajo, E. Anda Apiñániz, N Castro Unanua, J.M. Zubiria Gortazar |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Everolimus Triglyceride business.industry Intestinal Neuroendocrine Tumor Hypertriglyceridemia Cancer General Medicine medicine.disease Gastroenterology chemistry.chemical_compound chemistry Internal medicine Medicine Acute pancreatitis Pancreatitis business Adverse effect medicine.drug |
| Zdroj: | Anales del Sistema Sanitario de Navarra. 43:103-106 |
| ISSN: | 1137-6627 |
| DOI: | 10.23938/assn.0859 |
| Popis: | Everolimus is an mTOR inhibitor, approved as a treatment for cancer and as an immunosuppressant agent in solid organ transplantation; it frequently produces toxic metabolic effects, particularly of the most severe kind. Its use can cause hyperglycemia, hypercholesterolemia and hypertriglyceridemia; thus, metabolic values should be monitored regularly to prevent these adverse events. We present the case of a woman with an intestinal neuroendocrine tumor who developed two episodes of acute pancreatitis, secondary to severe hypertriglyceridemia caused by everolimus. After treatment with fibrates and omega-3, triglyceride levels returned to baseline, without developing new metabolic or digestive complications. Targeted levels of triglyceride for cancer patients treated with everolimus, should be below 500 or 300 mg/dL, depending on whether life expectancy is less or longer than one year, respectively. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|